miR‑1271 enhances the sensitivity of colorectal cancer cells to cisplatin

Yao,Huixiang; Sun,Qun; Zhu,Jinshui

doi:10.3892/etm.2019.7501

miR‑1271 enhances the sensitivity of colorectal cancer cells to cisplatin

Authors:
- Huixiang Yao
- Qun Sun
- Jinshui Zhu
View Affiliations

Affiliations: Department of Gastroenterology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, P.R. China
Published online on: April 18, 2019 https://doi.org/10.3892/etm.2019.7501
Pages: 4363-4370
Copyright: © Yao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The high mortality of colorectal cancer (CRC) is likely caused by early invasion and metastasis. The chemoresistance of tumor cells is the critical reason for treatment failure. The present study aimed to develop targeted solutions to overcome chemotherapy drug resistance in CRC. CCK‑8 assay was used to examine SW480 cell viability. SW480 cell apoptosis was examined using flow cytometry. The present study demonstrated that the expression of miR‑1271 was significantly decreased in CRC tumors and cell lines compared with control tissues. Furthermore, the expression of microRNA (miR)‑1271 was increased and decreased following the transfection of miR‑1271 mimics and an inhibitor, respectively. Furthermore, miR‑1271 regulated mammalian target of rapamycin (mTOR) expression by directly binding to the mTOR 3'‑untranslated region and the relative luciferase activity of mTOR was decreased following miR‑1271 overexpression. The results of the present study indicate that miR‑1271 may be a potential target for anti‑CRC therapy, particularly in the sensitivity of chemotherapeutic drugs. miR‑1271 may therefore enhance the sensitivity of CRC cells to chemotherapy drugs and provide a novel approach for the gene therapy of CRC.

View Figures

View References

1	Li S, Li C and Fang Z: MicroRNA 214 inhibits adipocyte enhancer-binding protein 1 activity and increases the sensitivity of chemotherapy in colorectal cancer. Oncol Lett. 17:55–62. 2019.PubMed/NCBI
2	Tie Y, Chen C, Yang Y, Qian Z, Yuan H, Wang H, Tang H, Peng Y, Du X and Liu B: Upregulation of let-7f-5p promotes chemotherapeutic resistance in colorectal cancer by directly repressing repressing several pro-apoptotic proteins. Oncol Lett. 15:8695–8702. 2018.PubMed/NCBI
3	Lo Russo G, Proto C and Garassino MC: Afatinib in the treatment of squamous non-small cell CRC: A new frontier or an old mistake? Transl Lung Cancer Res. 5:110–114. 2016.PubMed/NCBI
4	Kazandjian D, Suzman DL, Blumenthal G, Mushti S, He K, Libeg M, Keegan P and Pazdur R: FDA approval summary: Nivolumab for the treatment of metastatic non-small cell CRC with progression on or after platinum-based chemotherapy. Oncologist. 21:634–642. 2016. View Article : Google Scholar : PubMed/NCBI
5	Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, Narwal R, Steele K, Gu Y, Karakunnel JJ and Rizvi NA: Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell CRC: A multicentre, phase 1b study. Lancet Oncol. 17:299–308. 2016. View Article : Google Scholar : PubMed/NCBI
6	Zhou YY, Hu ZG, Zeng FJ and Han J: Clinical profile of cyclooxygenase-2 inhibitors in treating non-small cell CRC: A meta-analysis of nine randomized clinical trials. PLoS One. 11:e01519392016. View Article : Google Scholar : PubMed/NCBI
7	Fenchel K, Sellmann L and Dempke WC: Overall survival in non-small cell CRC-what is clinically meaningful? Transl Lung Cancer Res. 5:115–119. 2016.PubMed/NCBI
8	Shi X, Xiao L, Mao X, He J, Ding Y, Huang J, Peng C and Xu Z: miR-205-5p mediated downregulation of PTEN contributes to cisplatin resistance in C13K human ovarian cancer cells. Front Genet. 9:5552018. View Article : Google Scholar : PubMed/NCBI
9	Wu D, Lu P, Mi X and Miao J: Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting pi3K p85. Arch Gynecol Obstet. 297:699–707. 2018. View Article : Google Scholar : PubMed/NCBI
10	Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
11	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
12	Huang R, Lin JY and Chi YJ: miR-519d reduces the 5-fluorouracil resistance in colorectal cancer cells by down-regulating the expression of CCND1. Eur Rev Med Pharmacol Sci. 22:2869–2875. 2018.PubMed/NCBI
13	Paliouras AR, Monteverde T and Garofalo M: Oncogene-induced regulation of microrna expression: Implications for cancer initiation, progression and therapy. Cancer Lett. 421:152–160. 2018. View Article : Google Scholar : PubMed/NCBI
14	Zhang C, Qian D, Zhao H, Lv N, Yu P and Sun Z: miR17 improves insulin sensitivity through inhibiting expression of ask1 and anti-inflammation of macrophages. Biomed Pharmacother. 100:448–454. 2018. View Article : Google Scholar : PubMed/NCBI
15	Rupaimoole R, Calin GA, Lopez-Berestein G and Sood AK: miRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discov. 6:235–246. 2016. View Article : Google Scholar : PubMed/NCBI
16	Yin W, Shi L and Mao Y: miR-194 regulates nasopharyngeal carcinoma progression by modulating MAP3K3 expression. FEBS Open Bio. 9:43–52. 2018. View Article : Google Scholar : PubMed/NCBI
17	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
18	Kaalund SS, Venø MT, Bak M, Møller RS, Laursen H, Madsen F, Broholm H, Quistorff B, Uldall P, Tommerup N, et al: Aberrant expression of miR-218 and miR-204 in human mesial temporal lobe epilepsy and hippocampal sclerosis-convergence on axonal guidance. Epilepsia. 55:2017–2027. 2014. View Article : Google Scholar : PubMed/NCBI
19	Shen J and Li M: Microrna-744 inhibits cellular proliferation and invasion of colorectal cancer by directly targeting oncogene notch1. Oncol Res. 2018. View Article : Google Scholar
20	Zhang Q, Zhang B, Sun L, Yan Q, Zhang Y, Zhang Z, Su Y and Wang C: MicroRNA-130b targets PTEN to induce resistance to cisplatin in lung cancer cells by activating Wnt/β-catenin pathway. Cell Biochem Funct. 36:194–202. 2018. View Article : Google Scholar : PubMed/NCBI
21	Gao Y, Ma H, Gao C, Lv Y, Chen X, Xu R, Sun M, Liu X, Lu X, Pei X and Li P: Tumor-promoting properties of miR-8084 in breast cancer through enhancing proliferation, suppressing apoptosis and inducing epithelial-mesenchymal transition. J Transl Med. 16:382018. View Article : Google Scholar : PubMed/NCBI
22	Hu Y, Guo X, Wang J, Liu Y, Gao H, Fan H, Nong X, Yang X, Liu M, Li S and Tang H: A novel microrna identified in hepatocellular carcinomas is responsive to lef1 and facilitates proliferation and epithelial-mesenchymal transition via targeting of nfix. Oncogenesis. 7:222018. View Article : Google Scholar : PubMed/NCBI
23	Xia D, Tian S, Chen Z, Qin W and Liu Q: miR302a inhibits the proliferation of esophageal cancer cells through the mapk and PI3K/Akt signaling pathways. Oncol Lett. 15:3937–3943. 2018.PubMed/NCBI
24	Yu Z, Xu N, Yang W, Liu Y and Yan F: Microrna-411 promoted the osteosarcoma progression by suppressing MTSS1 expression. Environ Sci Pollut Res Int. 25:12064–12071. 2018. View Article : Google Scholar : PubMed/NCBI
25	Sun X, Zhai H, Chen X, Kong R and Zhang X: MicroRNA-1271 suppresses the proliferation and invasion of colorectal cancer cells by regulating metadherin/Wnt signaling. J Biochem Mol Toxicol. 32:2018.Doi: 10.1002/jbt.22028. View Article : Google Scholar
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Xing F, Wang S and Zhou J: The expression of microRNA-598 inhibits ovarian cancer cell proliferation and metastasis by targeting URI. Mol Ther Oncolytics. 12:9–15. 2018. View Article : Google Scholar : PubMed/NCBI
28	Wang Y and Qin H: miR-338-3p targets RAB23 and suppresses tumorigenicity of prostate cancer cells. Am J Cancer Res. 8:2564–2574. 2018.PubMed/NCBI
29	Weng L, Ma J, Jia YP, Wu SQ, Liu BY, Cao Y, Yin X, Shang MY and Mao AW: miR-4262 promotes cell apoptosis and inhibits proliferation of colon cancer cells: Involvement of GALNT4. Am J Transl Res. 10:3969–3977. 2018.PubMed/NCBI
30	Toiyama Y, Okugawa Y, Fleshman J, Richard Boland C and Goel A: MicroRNAs as potential liquid biopsy biomarkers in colorectal cancer: A systematic review. Biochim Biophys Acta Rev Cancer. 1870:274–282. 2018. View Article : Google Scholar : PubMed/NCBI
31	Yang M, Shan X, Zhou X, Qiu T, Zhu W, Ding Y, Shu Y and Liu P: miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. Anticancer Agents Med Chem. 14:884–891. 2014. View Article : Google Scholar : PubMed/NCBI
32	Shao Q, Zhang P, Ma Y, Lu Z, Meng J, Li H, Wang X, Chen D, Zhang M, Han Y, et al: Microrna-139-5p affects cisplatin sensitivity in human nasopharyngeal carcinoma cells by regulating the epithelial-to-mesenchymal transition. Gene. 652:48–58. 2018. View Article : Google Scholar : PubMed/NCBI
33	Yang Y, Liu L, Zhang Y, Guan H, Wu J, Zhu X, Yuan J and Li M: miR-503 targets pi3K p85 and IKK-beta and suppresses progression of non-small cell CRC. Int J Cancer. 135:1531–42. 2014. View Article : Google Scholar : PubMed/NCBI
34	Chen Z, Gao YJ, Hou RZ, Ding DY, Song DF, Wang DY and Feng Y: MicroRNA-206 facilitates gastric cancer cell apoptosis and suppresses cisplatin resistance by targeting MAPK2 signaling pathway. Eur Rev Med Pharmacol Sci. 23:171–180. 2019.PubMed/NCBI
35	Baguley BC: Multiple drug resistance mechanisms in cancer. Mol Biotechnol. 46:308–316. 2010. View Article : Google Scholar : PubMed/NCBI
36	Li J, Sun H, Liu T and Kong J: MicroRNA-423 promotes proliferation, migration and invasion and induces chemoresistance of endometrial cancer cells. Exp Ther Med. 16:4213–4224. 2018.PubMed/NCBI
37	Wei Y, Wu S, Xu W, Liang Y, Li Y, Zhao W and Wu J: Depleted aldehyde dehydrogenase 1A1 (ALDH1A1) reverses cisplatin resistance of human lung adenocarcinoma cell A549/DDP. Thorac Cancer. 8:26–32. 2017. View Article : Google Scholar : PubMed/NCBI
38	Li L, Sun JX, Wang XQ, Liu XK, Chen XX, Zhang B, He ZD, Liu DZ, Chen LX, Wang LW and Huang Z: Notoginsenoside R7 suppresses cervical cancer via PI3K/PTEN/Akt/mTOR signaling. Oncotarget. 8:109487–109496. 2017. View Article : Google Scholar : PubMed/NCBI
39	Fujishita T, Kojima Y, Kajino-Sakamoto R, Taketo MM and Aoki M: Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma. Oncogene. 36:6480–6489. 2017. View Article : Google Scholar : PubMed/NCBI
40	Wang C, Liu E, Li W, Cui J and Li T: miR-3188 inhibits non-small cell lung cancer cell proliferation through FOXO1-mediated mTOR-p-PI3K/AKT-c-JUN signaling pathway. Front Pharmacol Dec. 9:13622018. View Article : Google Scholar
41	Gao S, Zhao Z, Wu R, Wu L, Tian X and Zhang Z: miR-146b inhibits autophagy in prostate cancer through affecting PTEN/AKT/mTOR signaling pathway. Aging (Albany NY). 11:2842019. View Article : Google Scholar : PubMed/NCBI
42	Song L, Zhou Z, Gan Y, Li P, Xu Y, Zhang Z, Luo F, Xu J, Zhou Q and Dai F: Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p. J Cell Biochem. Dec 11–2018.(Epub ahead of print). doi: 10.1002/jcb.28244.